APOL1 variant alleles associate with reduced risk for opportunistic infections in HIV infection
Year: 2021
Type: review
Abstract: Apolipoprotein L1 (APOL1), an innate immune factor against African trypanosoma brucei, inhibits HIV-1 in vitro. The impact of APOL1 G1-G2 variants on HIV-1-associated opportunistic infections (OIs) is unknown. Here, we report findings from a metaanalysis of four HIV/AIDS prospective cohorts (ALIVE, LSOCA, MACS, and WIHS) including 2066 African American participants. Using a global test combining all four cohorts, carriage of two APOL1 variant alleles is associated with a 50% reduction in odds of OI (combined OR 0.50, 95% CI 0.33-0.76). Subgroup analysis of OI etiological categories (viral, parasitic, fungal and Mycobacterial) suggests the possibility of specific protection from fungal infections (OR 0.54. 95% CI 0.32-0.93; PBonferroni corrected = 0.08). We observe an association of APOL1 variant alleles with host protection against OI in HIV-positive individuals. The study suggests a broader role of APOL1 variant alleles in innate immunity in vivo.
Source: Communications Biology
Institutions: Frederick National Laboratory for Cancer Research, Izmir Institute of Technology, Johns Hopkins University, Johns Hopkins Medicine, Center for Cancer Research, Leidos Biomedical Research Inc. (United States), École Centrale de Nantes, Inserm, Centre Hospitalier Universitaire de Nantes, Institut de Transplantation Urologie en Nephrologie, Université de Nantes, Nantes Université, University of California, San Francisco, San Francisco VA Health Care System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,290
Funders: U.S. Department of Health and Human Services, Northwestern University, Icahn School of Medicine at Mount Sinai, Johns Hopkins University, Frederick National Laboratory for Cancer Research, Georgia Clinical and Translational Science Alliance, National Institutes of Health, University of California, San Francisco, Johns Hopkins Bloomberg School of Public Health, Center for AIDS Research, University of Alabama at Birmingham, National Institute on Alcohol Abuse and Alcoholism, National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute of Mental Health, National Institute on Drug Abuse, National Eye Institute, National Cancer Institute, National Institute on Deafness and Other Communication Disorders, National Institute of Nursing Research, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute of Dental and Craniofacial Research, National Center for Advancing Translational Sciences, National Institute on Minority Health and Health Disparities, Center for AIDS Research, University of North Carolina at Chapel Hill
Awards: G1059889365, G1568124596, G1653542590, G1913134163, G1920318090, G2430231950, G2435036225, G2840405583, G2905730301, Studies of Ocular Complications of AIDS - Reading Center, G311558797, G3126495888, G3503792436, G3547560438, G386607036, G3869857964, G409006598, Studies of Ocular Complications of AIDS - Chairman's Office, G4585269469, G4586057299, G4756138391, G4953964255, G4988656331, G5147848267, Studies of Ocular Complications of AIDS - Coordinating Center, G5660189159, G5699974340, G5737582129, G5817808917, G5863844756, G5867949827, Clinical and Translational Science Institute, G5888954722, G5897683787, G5900455136, G6268431163, G6384504179, G6396423216, Natural History of HIV Infection in Injection Drug Users, G6509896931, G6670118009, G6696250203, G6759032351, G6809319421, G6990385686, G7152846654, G7454986501, G775892330, G7807729167, G8092408809, G9000034708, G9000080293, G9000119194, University of Pittsburgh MACS/WIHS CCS, MACS/WIHS -CCS, SF Bay Area MACS/WIHS Combined Cohort Study, UNC MACS/WIHS Combined Cohort Study Clinical Research Site, Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies, Center for AIDS Research at Emory University, Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS Research, Los Angeles CRS for the MACS/WIHS Combined Cohort Study, Data Analysis and Coordination Center for the MACS-WIHS Combined Cohort Study, MACS/WIHS Combined Cohort Study: Cook County Clinical Research Site (CC_CRS), The University of North Carolina Center for AIDS Research, MACS/WIHS Combined Cohort Study: Brooklyn Clinical Research Site (Bklyn CRS), Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center, Atlanta MACS/WIHS Combined Cohort Study Clinical Research Site, UAB-MISS MACS/WIHS Combined Cohort Study, Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS), UAB Center for AIDS Research (CFAR), G929137571
OpenAlex ID: W3133636662